The lymphatic system in malignant pleural effusion :Drain or immune switch?

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 6, 2014, Pages 626-627

  Marazioti, Antonia ^a   Stathopoulos, Georgios T ^a   Blackwell, Timothy S ^b  

^a UNIVERSITY OF PATRAS   (Greece)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; STAT1 PROTEIN; STAT3 PROTEIN;

CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; COLON ADENOCARCINOMA; EDITORIAL; HELPER CELL; HUMAN; LUNG ADENOCARCINOMA; LYMPHATIC SYSTEM; MALIGNANT PLEURA EFFUSION; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL;

ANIMALS; PLEURAL EFFUSION, MALIGNANT; TH1 CELLS; TH17 CELLS;

EID: 84896535659     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201401-0140ED     Document Type: Editorial

References (15)

1. Maskell NA. Treatment options for malignant pleural effusions: Patient preference does matter. JAMA 2012;307:2432-2433.
2. Burgers JA, Kunst PW, Koolen MG, Willems LN, Burgers JS, van den Heuvel M. Pleural drainage and pleurodesis: Implementation of guidelines in four hospitals. Eur Respir J 2008;32:1321-1327.
3. Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: Tumor-host interactions unleashed. Am J Respir Crit Care Med 2012;186:487-492.
4. Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson WE, Bilaceroglu S, Peterson TE, Mitchell D, Yull FE, Light RW, et al. Nuclear Factor-kB Affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 2006;34:142-150.
5. Stathopoulos GT, Sherrill TP, Karabela SP, Goleniewska K, Kalomenidis I, Roussos C, Fingleton B, Yull FE, Peebles RS, Blackwell TS. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am J Respir Crit Care Med 2010;182:1273-1281.
6. Marazioti A, Kairi CA, Spella M, Giannou AD, Magkouta S, Giopanou I, Papaleonidopoulos V, Kalomenidis I, Snyder LA, Kardamakis D, et al. Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion. PLoS ONE 2013;8:e71207.
7. Stathopoulos GT, Moschos C, Loutrari H, Kollintza A, Psallidas I, Karabela S, Magkouta S, Zhou Z, Papiris SA, Roussos C, et al. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med 2008;178:50-59.
8. Stathopoulos GT, Psallidas I, Moustaki A, Moschos C, Kollintza A, Karabela S, Porfyridis I, Vassiliou S, Karatza M, Zhou Z, et al. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst 2008;100:1464-1476.
9. Lin H, Tong ZH, Xu QQ,Wu XZ, Wang XJ, Jin XG, MaWL, Cheng X, Zhou Q, Shi HZ. Interplay of Th1 and Th17 cells in murine models of malignant pleural effusion. Am J Respir Crit Care Med 2014;189:697-706.
10. Chen YQ, Shi HZ, Qin XJ, Mo WN, Liang XD, Huang ZX, Yang HB, Wu C. CD41CD251 regulatory T lymphocytes in malignant pleural effusion. Am J Respir Crit Care Med 2005;172:1434-1439.
11. Qin XJ, Shi HZ, Deng JM, Liang QL, Jiang J, Ye ZJ. CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res 2009;15:2231-2237.
12. Ye ZJ, Zhou Q, Yin W, Yuan ML, Yang WB, Xiong XZ, Zhang JC, Shi HZ. Differentiation and immune regulation of IL-9-producing CD41 T cells in malignant pleural effusion. Am J Respir Crit Care Med 2012; 186:1168-1179.
13. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009;16:183-194.
14. Martin F, Apetoh L, Ghiringhelli F. Controversies on the role of Th17 in cancer: A TGF-b-dependent immunosuppressive activity? Trends Mol Med 2012;18:742-749.
15. Basu R, Hatton RD, Weaver CT. The Th17 family: Flexibility follows function. Immunol Rev 2013;252:89-103.